MicroPort NeuroTech (HKSE:02172) FCF Margin % : -18.10% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is MicroPort NeuroTech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MicroPort NeuroTech's Free Cash Flow for the six months ended in Dec. 2023 was HK$-72.6 Mil. MicroPort NeuroTech's Revenue for the six months ended in Dec. 2023 was HK$400.8 Mil. Therefore, MicroPort NeuroTech's FCF Margin % for the quarter that ended in Dec. 2023 was -18.10%.

As of today, MicroPort NeuroTech's current FCF Yield % is -1.06%.

The historical rank and industry rank for MicroPort NeuroTech's FCF Margin % or its related term are showing as below:

HKSE:02172' s FCF Margin % Range Over the Past 10 Years
Min: -7.34 Med: 5.9 Max: 32.13
Current: -7.34

During the past 5 years, the highest FCF Margin % of MicroPort NeuroTech was 32.13%. The lowest was -7.34%. And the median was 5.90%.

HKSE:02172's FCF Margin % is ranked worse than
50.61% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: -7.11 vs HKSE:02172: -7.34

MicroPort NeuroTech FCF Margin % Historical Data

The historical data trend for MicroPort NeuroTech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort NeuroTech FCF Margin % Chart

MicroPort NeuroTech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

3.58

5.90

25.97

32.13

-7.34

MicroPort NeuroTech Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			23.93	7.08	47.24	5.85	-18.10

Competitive Comparison of MicroPort NeuroTech's FCF Margin %

For the Medical Devices subindustry, MicroPort NeuroTech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MicroPort NeuroTech's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroTech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MicroPort NeuroTech's FCF Margin % falls into.

MicroPort NeuroTech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MicroPort NeuroTech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-53.404	/	728.045
	=	-7.34 %

MicroPort NeuroTech's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-72.553	/	400.794
	=	-18.10 %

MicroPort NeuroTech FCF Margin % Related Terms

Thank you for viewing the detailed overview of MicroPort NeuroTech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MicroPort NeuroTech (HKSE:02172) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort NeuroTech Ltd (HKSE:02172) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1661 Zhangdong Road, Pudong New Area, Shanghai, CHN

Website

https://www.medneurotech.com

MicroPort NeuroTech Ltd is into the neuro-interventional medical device industry, dedicated to providing innovative solutions for physicians and patients. The company boast a comprehensive portfolio of approved therapeutic products covering all of the three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke.

Executives

Hu Yibin
Biolink Biomedical Ltd.	2201 Interest of corporation controlled by you
Blossom Vision Limited	2201 Interest of corporation controlled by you
Lion Fish Limited	2201 Interest of corporation controlled by you
Suntera Corporate Trustees (hong Kong) Limited	2301 Trustee
Thriving Hope Limited	2201 Interest of corporation controlled by you
Biolink Fund Limited Partnership	2201 Interest of corporation controlled by you
Biolink Limited	2101 Beneficial owner
Microport Scientific Corporation
Microport Scientific Investment Ltd
Maxwell Maxcare Science Foundation Limited
We'tron Capital Limited

MicroPort NeuroTech (HKSE:02172) Headlines

No Headlines